Moderna, Inc SC TO-C, filed Oct 10, 2025
Moderna, Inc. (MRNA)
SC TO-C
2025-10-10
View Original
Added on
October 15, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )
Moderna, Inc.
(Name of Subject Company (Issuer) and Filing Person (as Offeror))
Options to Purchase Common Stock, par value $0.0001 per share
(Title of Class of Securities)
60770K107
(CUSIP Number of Class of Securities)
Stéphane Bancel
Chief Executive Officer
Moderna, Inc.
325 Binney Street
Cambridge, Massachusetts 02142
(617) 714-6500
(Name, address, and telephone number of person authorized to receive notices and communications on behalf of filing persons)
CALCULATION OF FILING FEE
|
Transaction Value (1)
|
Amount of Filing Fee (2)
|
|
|
N/A
|
N/A
|
|
*
|
Pursuant to General Instruction D to Schedule TO, a filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.
|
|
☐
|
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
|
|
Amount Previously Paid: Not applicable.
|
Filing Party: Not applicable.
|
|
|
Form or Registration No.: Not applicable.
|
Date Filed: Not applicable.
|
|
☒
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
☐
|
third-party tender offer subject to Rule 14d-1.
|
|
☒
|
issuer tender offer subject to Rule 13e-4.
|
|
☐
|
going-private transaction subject to Rule 13e-3.
|
|
☐
|
amendment to Schedule 13D under Rule 13d-2.
|
Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
|
☐
|
Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
|
|
☐
|
Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
|
Attached are communications to employees of Moderna, Inc., a Delaware corporation (the “Company”), first circulated on October 10, 2025 (the “Employee Communications”), related to the proposed stock option exchange program that would allow
certain employees who are not executive officers to exchange significantly out-of-the-money or “underwater” stock options, meaning outstanding stock options that have an exercise price that is significantly greater than the market price for the
Company’s common stock, for the issuance of new stock options that will be exercisable for fewer shares of the Company’s common stock, with an exercise price equal to the fair market value of the Company’s common stock on the grant date of the
new stock options and with new vesting terms (the “Option Exchange Program”). The Option Exchange Program is subject to Moderna shareholder approval at a Special Meeting of Shareholders to be held on November 12, 2025, and is further described in
the preliminary proxy statement (the “Preliminary Proxy Statement”) that was filed with the Securities and Exchange Commission (“SEC”) on October 3, 2025.
Neither the Preliminary Proxy Statement nor Employee Communications constitute an offer to holders of the Company’s outstanding stock options to exchange those options. The
Option Exchange Program will only be implemented, if at all, if the Company’s shareholders first approve the Option Exchange Program.
The Option Exchange Program has not yet commenced. Even if shareholder approval is obtained, the Company may decide not to implement the Option Exchange Program. The Company will
file a Tender Offer Statement on Schedule TO with the SEC if and when the Option Exchange Program commences. Option holders should read the Tender Offer Statement on Schedule TO and other related materials when those materials become available,
because they will contain important information about the Option Exchange Program.
The Company’s shareholders and option holders will be able to obtain the written materials described above and the other documents filed by the Company with the SEC free of
charge from the SEC’s website at www.sec.gov or by directing a written request to: Corporate Secretary, at 325 Binney Street, Cambridge, Massachusetts 02142.
Item 12. Exhibits.
Exhibit 99.1
Subject: Powerful Investments in You
Your Health. Your Wealth. Your Future.
At Moderna, our greatest strength is you. That’s why we’re all in on designing benefits For You—to champion your health, support your loved ones, and help you build the future
you deserve. We’re not just keeping up; we’re raising the bar with bold, people-first investments that reflect how much we value your contributions.
Because your decisions matter, we’re making it easier than ever to explore your options with powerful tools, personalized resources, and support every step of the way. That’s why we wanted to share reminders on two
programs: the Option Exchange Program and U.S. Benefits Enrollment.
Option Exchange Program: For Your Financial Well-Being
The Option Exchange Program is a unique, employee-first investment in you. It reflects the innovative ways we’re supporting your long-term financial well-being. This is your opportunity to restore the potential value
of your stock options and build toward lasting value. The Option Exchange is subject to shareholder approval, and if approved, will launch in mid-November. To support your decision making, we’ve launched a new resource hub at go/OptionExchange
with:
October Informational Sessions with the Equity team (invites to follow):
|
•
|
Tuesday, October 21 | 8:00–9:00 p.m. EST
|
|
•
|
Wednesday, October 22 | 8:00–9:00 a.m. EST
|
|
•
|
Thursday, October 23 | 2:00–3:00 p.m. EST
|
Coming October 20:
|
•
|
Brochure outlining how the program works
|
|
•
|
Modeling tool to explore personalized scenarios
|
|
•
|
Interactive GPT: our AI powered assistant to help answer your questions
|
|
•
|
Location-specific tax considerations
|
|
•
|
FAQs to answer your questions
|
U.S. Benefits Open Enrollment: For Your and Your Loved Ones’ Well-Being
[…]
We encourage you to take advantage of these resources to make confident choices for your future.
Because when you thrive, so do we.
October Information Sessions Meeting Invites
Subject: Learn More About the Option Exchange Program!
Body of Invite (calendar description):
We’re excited to invite you to an Option Exchange Information Session — your chance to learn more about this unique opportunity and how it works!
We’re excited to invite you to an Option Exchange Information Session — your chance to learn more about this unique opportunity and how it works!
During the session, we’ll:
|
•
|
Review the key design features of the program
|
|
•
|
Walk through an illustrative example
|
|
•
|
Share additional resources to help you make the decision that’s right for you
|
Three sessions are available — choose the one that works best for you.
|
•
|
Session 1: Tuesday, October 21 | 8:00–9:00 p.m. EST
|
|
•
|
Session 2: Wednesday, October 22 | 8:00–9:00 a.m. EST
|
|
•
|
Session 3: Thursday, October 23 | 2:00–3:00 p.m. EST
|
No RSVP required — just join the session that fits your schedule.
This communication is not an offer to exchange any options. The option exchange has not yet commenced, and there can be no assurance that it will be implemented even if it is approved
by Moderna shareholders. Moderna will file a Tender Offer Statement on Schedule TO with the SEC if and when the option exchange commences. If Moderna commences the option exchange, we will provide employees who are eligible to participate in the
exchange program with written materials explaining the precise terms and timing of the program. You should read these materials carefully when they become available, because they will contain important information about the option exchange. You
will also be able to obtain the tender offer statement and other documents filed by Moderna with the SEC free of charge from the SEC’s website at www.sec.gov.